Hereditary transthyretin amyloidosis (ATTRv) with polyneuropathy (ATTR-PN) is a rare genetic disorder. |
Survival in patients with ATTR-PN is largely characterized by and dependent on associated cardiac damage, but the impact of non-cardiac characteristics on survival are less defined. |
This study sought to assess the impact of non-cardiac baseline characteristics on survival in ATTR-PN. |
Survival in patients with ATTR-PN was highly variable and affected by non-Val30Met mutation and non-cardiac baseline characteristics, such as autonomic dysfunction, large fiber involvement, and late-onset disease. |
Introduction
Methods
Record identification and selection
-
Human studies of adults (aged ≥ 18 years).
-
Primary report.
-
Reported survival among persons with ATTR-PN.
-
Follow-up time for survival assessment was ≥ 5 years.
-
Sample size is ≥ 10.
-
Survival was assessed from a defined baseline event (symptom onset, diagnosis, or treatment initiation).
-
Reported whether patients received disease-modifying pharmacologic treatment or LTx.
-
Patients were symptomatic at the baseline event (assumed unless noted otherwise).
Data Extraction and Synthesis
Compliance with Ethics Statement
Results
First author of study, year of publication [reference number] | N (size of cohort) | Country | Diagnostic method(s) | Baseline periodicitya | Follow-up (years)b | Evidence class, risk of biasc |
---|---|---|---|---|---|---|
Adams, 2000 [19] | 45 | Multiplei | Tissue biopsy + genetic testing | 1993–1999 | 6 | 1, Low |
Adams, 2018 [20] | 225 | Multiple | NR | 2013–2016 | 7 | 1, Low |
215 | France | Tissue biopsy + genetic testing | 1993–2011 | 10 | 1, Low | |
Arruda-Olson, 2013 [22] | 37 | USA | Tissue biopsy | 1980–2010 | 6 | 2, Low |
Barrosso, 2017 [23] | 75 | Mixed | Tissue biopsy + genetic testing | NR–2014 | 10 | 1, Low |
Bittencourt, 2002 [24] | 24 | Brazil | Tissue biopsy + genetic testingo | 1993–1999 | 7 | 2, Moderate |
Carvalho, 2002 [25] | 35 | Portugal | Genetic testing | 1992–2000 | 5 | 2, Moderate |
Coelho, 2018 [26] | 3160 | Portugal | Mixed | 1992–2016 | 24 | 2, Moderate |
Coutinho, 2013 [27] | 106e | Portugal | Genetic testing | 1998–2010 | 13 | 1, Moderate |
Coutinho, 2017 [27] | 232 | Portugal | NR | 1998–2015 | 15 | 1, Moderate |
Ericzon, 2015 [28] | 1623 | Multiplej | NR | 1990–2010 | 20 | 2, High |
Franz, 2013 [29] | 21 | Germany | Genetic testing | 1996–2011 | 10 | 2, Moderate |
Gonzalez-Lopez, 2018 [30] | 118 | Spain | NR | NR | 25 | 3, High |
Ines, 2018 [31] | 3160 | Portugalk | NR | NR–2016 | 35 | 3, High |
Kawaji, 2014 [32] | 27 | Japan | Tissue biopsy + genetic testing | 1987–2011 | 7 | 1, Low |
Lagarto, 2016 [33] | 116 | Portugal | Genetic testing | 2006–2014 | 7 | 2, Moderate |
Loavenbruck, 2016 [34] | 41f | USA | Tissue biopsy + genetic testing | 1993–2013 | 20 | 1, Low |
Lobato, 2004 [35] | 62 | Portugal | Tissue biopsy + genetic testingp | 1989–2000 | 9 | 1, Moderate |
Mariani, 2015 [36] | 194 | Francel | Tissue biopsy + genetic testing | 1988–2010 | 25 | 2, Low |
Munar-Ques, 2005 [37] | 102 | Spain | Tissue biopsy ± genetic testing | 1976–2003 | 29r | 3, Moderate |
Ohya, 2011 [38] | 34 | Japan | Tissue biopsy ± genetic testing | 1994–2006 | 10 | 3, Moderate |
Okamoto, 2011 [39] | 104 | Sweden | Tissue biopsy ± genetic testing | 1990–2008 | 25 | 1, Low |
Okamoto, 2009 [40] | 141 | Sweden | Tissue biopsy ± genetic testing | 1990–2008 | 20 | 1, Low |
Okumura, 2016 [41] | 65 | Japan | Genetic testing | 1990–2010 | 20 | 2, Moderate |
Plante-Bordeneuve, 1998 [42] | 65 | France | Genetic testing ± tissue biopsy | 1988–1997 | 10 | 2, High |
Suhr, 2016 [11] | 264 | Multiplej | NR | 1991–2012 | 10 | 2, High |
Suhr, 2002 [43] | 51g | Sweden | Tissue biopsy + genetic testing | 1990–2000 | 20 | 2, Moderate |
Swiecicki, 2015 [44] | 110 h | USA | Family history ± genetic testing | 1970–2013 | 8 | 4, High |
Takei, 2005 [45] | 43 | Japan | Genetic testing | 1993–2004 | 10 | 2, Moderate |
Tashima, 1998 [46] | 120 | Multiplem | Tissue biopsy + genetic testingq | 1973–1998 | 24 | 3, Moderate |
Wixner, 2015 [47] | 115 | Sweden | Tissue biopsy + genetic testing | 1990–2011 | 9 | 1, Low |
Yamamoto, 1998 [48] | 116 | Japan | Tissue biopsy + family history | 1974–1995 | 20 | 4, High |
Yamamoto, 2007 [49] | 86 | Multiplem | Tissue biopsy + genetic testing | 1990–2005 | 16 | 1, Low |
Yamashita, 2012 [50] | 80 | Multiplen | Tissue biopsy + genetic testing | 1990–2010 | 20 | 2, Low |
Yamashita, 2018 [51] | 104 | Japan | Tissue biopsy ± genetic testing | 2000–2017 | 10 | 2, Low |
Domaina | Description | Survival difference (years) | Mitigating factor(s) |
---|---|---|---|
Genotype | |||
Mariani, 2015 [36] | Val30Met vs. Non-Val30Met | 1 (8 vs. 7) | Among No LTx |
Mariani, 2015 [36] | Val30Met vs. Non-Val30Met | 4 (17 vs. 13) | Among LTx |
Sex/gender | |||
Munar-Ques, 2005 [37] | Female vs. male | − 1 (9 vs. 10) | None reported |
Okamoto, 2009 [40] | Female vs. male | ≥ 4 (≥ 25 vs. 21) | Among LTx |
Okamoto, 2009 [40] | Female vs. male | ≥ 4 (≥ 25 vs. 21) | Among LTx with early onset |
Okamoto, 2009 [40] | Female vs. male | ≥ 9 (≥ 20 vs. 11) | Among LTx with late onset |
Yamamoto, 1998 [48] | Female vs. male | 1 (11 vs. 10) | Among no LTx |
Pre-LTx disease duration | |||
Bittencourt, 2002 [24] | < 7 years vs. ≥ 7 years | ≥ 6 (≥ 7 vs. 1) | None reported |
Okamoto, 2009 [40] | < 7 years vs. ≥ 7 years | ≥ 4 (≥ 25 vs. 21) | None reported |
Suhr, 2002 [43] | < 7 years vs. ≥ 7 years | 3 (14 vs. 11) | Lower baseline mBMI in < 7 years |
Yamamoto, 2007 [49] | < 7 years vs. ≥ 7 years | ≥ 17 (≥ 20 vs. 3) | None reported |
Biometrics/symptoms | |||
Suhr, 2002 [43] | mBMI > 600 vs. < 600 (at LTx) | 3 (14 vs. 11) | Pre-LTx disease duration was < 7 vs. ≥ 7 years |
Yamamoto, 2007 [49] | mBMI > 600 vs. < 600 (at LTx) | ≥ 17 (≥ 20 vs. 3) | Pre-LTx disease duration was < 7 vs. ≥ 7 years |
Bittencourt, 2002 [24] | Serum albumin (at LTx) | ≥ 6 (≥ 7 vs. 1) | Among LTx |
Adams, 2000 [19] | Urinary incontinence (at LTx) | ≥ 4 (≥ 5 vs. 1) | Among LTx |